6L9.F Stock Surges 2400% in May 2026 After-Hours Trading

ViewRay, Inc. (6L9.F) experienced a dramatic 2400% surge in after-hours trading on May 1, 2026, reaching €0.025 per share on the XETRA exchange. The medical device manufacturer, which specializes in MRI-guided radiation therapy systems, saw trading volume spike to 3,500 shares, a massive 1,254% increase from its average daily volume of 279 shares. This extreme volatility reflects the stock’s troubled history, with 6L9.F trading down 99.4% over the past year. Despite the dramatic intraday bounce, investors should recognize this as a high-risk recovery attempt in a deeply distressed healthcare stock.

Understanding the 6L9.F Stock Price Explosion

The €0.025 price point represents a recovery from the day’s low of €0.001, but context matters here. ViewRay’s 6L9.F stock has collapsed from a 52-week high of €4.60 to a low of €0.0005, illustrating the severity of the company’s operational challenges. The after-hours surge likely reflects short-covering or speculative buying rather than fundamental improvement. Track 6L9.F on Meyka for real-time updates on this volatile medical device stock. The company’s market capitalization stands at approximately €207 million, down sharply from historical levels, signaling investor concern about its MRIdian radiation therapy platform’s commercial viability.

6L9.F Analysis: Financial Metrics Show Deep Distress

ViewRay’s financial position reveals why 6L9.F stock has deteriorated so severely. The company reports a negative EPS of -€0.55 and a negative PE ratio of -0.045, indicating ongoing losses. Operating margins are deeply negative at -104.8%, while the company burns cash with a free cash flow per share of -€0.53. The current ratio of 2.36 suggests adequate short-term liquidity, but this masks the fundamental problem: the company is unprofitable and consuming capital. Revenue per share of only €0.57 cannot support the cost structure, explaining why 6L9.F stock has become a distressed asset in the medical devices sector.

Market Sentiment: Trading Activity and Liquidation Pressure

The extreme volume spike in 6L9.F stock reflects forced liquidation and speculative repositioning rather than institutional confidence. With only 3,500 shares trading against an average of 279 shares, the relative volume reached 12.5x normal levels, indicating panic selling or short-squeeze dynamics. The stock’s 50-day moving average sits at €0.32, while the 200-day average is €2.72, showing the relentless downtrend. Meyka AI rates 6L9.F with a grade of C+ with a HOLD suggestion, reflecting the stock’s distressed valuation but acknowledging recovery potential if the company stabilizes operations. This grade factors in sector performance, financial metrics, and analyst consensus.

ViewRay Inc. Stock Outlook: Path Forward Remains Uncertain

ViewRay’s MRIdian technology addresses a real clinical need in cancer treatment, combining MRI imaging with radiation therapy to reduce side effects. However, the company’s inability to achieve profitability raises questions about market adoption and pricing power. With 2,950 full-time employees and headquarters in Oakwood, Ohio, ViewRay carries significant fixed costs. The stock’s recovery depends on accelerating MRIdian system sales and achieving operational efficiency. According to financial data sources, the company serves university hospitals, community centers, and cancer treatment facilities globally. Until revenue growth outpaces expenses, 6L9.F stock remains a high-risk turnaround play unsuitable for conservative investors.

Final Thoughts

ViewRay Inc.’s 6L9.F stock surged 2400% intraday on May 1, 2026, but faces serious structural issues. The unprofitable medical device company has negative cash flow and declined from €4.60 to €0.025, signaling investor doubt about its MRIdian platform’s commercial viability. High operating costs and limited revenue generation persist despite speculative interest. Meyka AI assigns a C+ grade and HOLD recommendation. Investors should treat this as a speculative turnaround, not a recovery opportunity, and conduct thorough due diligence before investing.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.